CRP and type 2 diabetes mellitus: Lee et al. conducted a one-year randomized controlled trial (RCT) where they found that administering high-dose modified-release nicotinic acid led to a considerable decrease in C-reactive protein (CRP) levels in patients with type 2 diabetes and cardiovascular disease [11].